Cervical Cancer Detection using bimodal Imaging Technique

Assessing the accuracy of Screening and Detection of Cervical Cancer using Fluorescence and Diffuse Reflectance Imaging

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/027999

Enrollment

110

Registered

2020-09-23

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N879- Dysplasia of cervix uteri, unspecified Health Condition 2: N72- Inflammatory disease of cervix uteri Health Condition 3: N880- Leukoplakia of cervix uteri Health Condition 4: N870- Mild cervical dysplasia Health Condition 5: N871- Moderate cervical dysplasia

Interventions

Intervention1: Cervical Imaging: The patient cervix is imaged using a multispectral imaging camera (Cerviscn) on exposure of cervix with a speculum Control Intervention1: Colposcopy guided biopsy: In

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients referred for Pap smear test 2.Patients with any kind of clinically suspected lesions in uterine cervix

Exclusion criteria

Exclusion criteria: 1.Patients who had undergone previously treatments for cancer 2.Patients with transmittable diseases

Design outcomes

Primary

Measure	Time frame
1.Patients will have possibility to get a more accurate screening for cervical cancer using cerviscan. 2.location of most malignant site for biopsy using cerviscan helps to minimize false negatives unnecessary biopsiesTimepoint: One week	—

Secondary

Measure	Time frame
Identification of areas of inflammationTimepoint: 1 week	—

Countries

India

Contacts

Public ContactDr Rekha Upadhya

Sascan Meditech Pvt Ltd

subhash.sascan@gmail.com9591345016

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026